Patisiran in Transthyretin Amyloidosis: A Promising Intervention for Cardiac Health and Quality of Life
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on November 17th, 2023
|
Transthyretin amyloidosis, stemming from the misfolding of the TTR protein, is a potentially lethal condition associated with cardiomyopathy leading to an average survival time of 2 to 6 years. Patisiran, an RNA interference agent, has the capability to bind to the TTR protein, facilitating its clearance. Consequently, a study was undertaken to explore the therapeutic impact of Patisiran on transthyretin amyloidosis.
In the phase 3 clinical trial, 360 patients diagnosed with transthyretin amyloidosis through biopsy were enrolled. The majority were diagnosed within the past year, with nearly two-thirds in stage 1. Over half of these patients maintained ambulatory status, while around 10% required movement assistance. Baseline assessments revealed an average 6-minute walking distance of approximately 350 meters. Patients were randomly assigned to receive intravenous treatment of either placebo or Patisiran every 3 weeks, with Patisiran administered at a dosage of 0.3 mg per kilogram of body weight, capped at 30 mg. After 12 months of treatment, Patisiran demonstrated efficacy in mitigating the decline in cardiac health, as evidenced by the 6-minute walking distance. The impact on patients' quality of life was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ), revealing an improvement in those treated with Patisiran compared to a decrease in the placebo group. While these findings are promising, it is crucial for physicians to be mindful of potential side effects. The study noted a higher incidence of arthralgia and muscle spasm in the Patisiran group, emphasizing the need for further research to evaluate the severity of these side effects in patients with other comorbidities and to elucidate the mechanism of action behind the adverse effect.
In the phase 3 clinical trial, 360 patients diagnosed with transthyretin amyloidosis through biopsy were enrolled. The majority were diagnosed within the past year, with nearly two-thirds in stage 1. Over half of these patients maintained ambulatory status, while around 10% required movement assistance. Baseline assessments revealed an average 6-minute walking distance of approximately 350 meters. Patients were randomly assigned to receive intravenous treatment of either placebo or Patisiran every 3 weeks, with Patisiran administered at a dosage of 0.3 mg per kilogram of body weight, capped at 30 mg. After 12 months of treatment, Patisiran demonstrated efficacy in mitigating the decline in cardiac health, as evidenced by the 6-minute walking distance. The impact on patients' quality of life was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ), revealing an improvement in those treated with Patisiran compared to a decrease in the placebo group. While these findings are promising, it is crucial for physicians to be mindful of potential side effects. The study noted a higher incidence of arthralgia and muscle spasm in the Patisiran group, emphasizing the need for further research to evaluate the severity of these side effects in patients with other comorbidities and to elucidate the mechanism of action behind the adverse effect.